A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.

Donor Selection Hematopoietic Stem Cell Transplantation / methods Humans Registries Transplantation Conditioning Transplantation, Autologous

Journal

Bone marrow transplantation

ISSN: 1476-5365

Titre abrégé: Bone Marrow Transplant

Pays: England

ID NLM: 8702459

Informations de publication

Date de publication:
02 2022

Historique:

received: 05 05 2021

accepted: 13 10 2021

revised: 04 10 2021

pubmed: 30 10 2021

medline: 22 4 2022

entrez: 29 10 2021

Statut: ppublish

Résumé

Traceability of patients who are candidates for Hematopoietic cell transplant (HCT) is crucial to ensure HCT program quality. Continuous knowledge of both a detailed registry from a HCT program and final exclusion causes can contribute to promoting a real-life vision and optimizing patient and donor selection. We analyzed epidemiological data reported in a 4 year-monocentric prospective registry, which included all patients presented as candidates for autologous (Auto) and/or allogeneic (Allo) HCT. A total of 543 patients were considered for HCT: 252 (42.4%) for Allo and 291 (57.6%) for Auto. A total of 98 (38.9%) patients were excluded from AlloHCT due to basal disease progression more commonly (18.2%). Seventy-six (30.2%) patients had an HLA identical sibling, whereas 147 (58.3%) patients had only Haplo. UD research was performed in 106 (42%) cases, significantly more often in myeloid than lymphoid malignancies (57% vs 28.7%, p < 0.001) but 61.3% were finally canceled, due to donor or disease causes in 72.4%. With respect to Auto candidates, a total of 60 (20.6%) patients were finally excluded; progression was the most common cause (12%). Currently, Haplo is the most frequent donor type. The high cancellation rate of UD research should be revised to optimize further donor algorithms.

Identifiants

DOI: 10.1038/s41409-021-01506-4 PMID: 34711917

pubmed: 34711917

doi: 10.1038/s41409-021-01506-4

pii: 10.1038/s41409-021-01506-4

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

176-182

Informations de copyright

Références

Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, et al. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. Bone Marrow Transplant. 2017;52:1367–71.

pubmed: 28346416 pmcid: 5629362 doi: 10.1038/bmt.2017.54

Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P, et al. Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation. Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation, and the European Leukemia Net. Haematologica. 2014;99:908–15.

pubmed: 24488562 pmcid: 4008105 doi: 10.3324/haematol.2013.096461

Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transpl. 2019;54:1525–52.

doi: 10.1038/s41409-019-0516-2

Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1739–48.

pubmed: 31621796 pmcid: 6802371 doi: 10.1001/jamaoncol.2019.3541

Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transpl. 2017;52:811–7.

doi: 10.1038/bmt.2017.34

Lown RN, Marsh SGE, Switzer GE, Latham KA, Madrigal JA, Shaw BE. Ethnicity, length of time on the register and sex predict donor availability at the confirmatory typing stage. Bone Marrow Transpl. 2014;49:525–31.

doi: 10.1038/bmt.2013.206

Karam E, Laporte J, Solomon SR, Morris LE, Zhang X, Holland HK, et al. Who is a better donor for recipients of allogeneic hematopoietic cell transplantation: a young HLA-mismatched haploidentical relative or an older fully HLA-matched sibling or unrelated donor? Biol Blood Marrow Transpl. 2019;25:2054–60.

doi: 10.1016/j.bbmt.2019.05.031

Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127:260–7.

pubmed: 26527675 pmcid: 4713163 doi: 10.1182/blood-2015-08-663823

McCurdy SR, Fuchs EJ. Selecting the best haploidentical donor. Semin Hematol. 2016;53:246–51.

pubmed: 27788762 doi: 10.1053/j.seminhematol.2016.08.001

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, et al. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transpl. 2020;55:681–94.

doi: 10.1038/s41409-019-0718-7

Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2016;51:1283–1300.

doi: 10.1038/bmt.2016.141

Cao K, Chopek M, Fernández-Viña MA. High and intermediate resolution DNA typing systems for class I HLA-A, B, C genes by hybridization with sequence-specific oligonucleotide probes (SSOP). Rev Immunogenet. 1999;1:177–208.

pubmed: 11253946

Erlich H. HLA DNA typing: past, present, and future. Tissue Antigens. 2012;80:1–11.

pubmed: 22651253 doi: 10.1111/j.1399-0039.2012.01881.x

Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303:1617–24.

pubmed: 20424252 pmcid: 3219875 doi: 10.1001/jama.2010.491

Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, et al. Worldwide network for blood and marrow transplantation recommendations for establishing a hematopoietic cell transplantation program, Part I: minimum requirements and beyond. Biol Blood Marrow Transpl. 2019;25:2322–9.

doi: 10.1016/j.bbmt.2019.05.002

Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43:676–81.

pubmed: 28061985 pmcid: 5283695 doi: 10.1053/j.seminoncol.2016.11.004

Dahi PB, Lazarus HM, Sauter CS, Giralt SA. Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma. Bone Marrow Transpl. 2019;54:943–60.

doi: 10.1038/s41409-018-0378-z

Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS. Acute myeloid leukemia: the good, the bad, and the ugly. Am Soc Clin Oncol Educ Book. 2018;38:555–73.

pubmed: 30231330 doi: 10.1200/EDBK_199519

von Tresckow B, Engert A. The role of autologous transplantation in Hodgkin lymphoma. Curr Hematol Malig Rep. 2011;6:172–9.

doi: 10.1007/s11899-011-0091-0

Lahoud OB, Sauter CS, Hamlin PA, Dahi PB. High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma. Curr Oncol Rep. 2015;17:42.

pubmed: 26201264 pmcid: 5542393 doi: 10.1007/s11912-015-0465-x

Hu B, Jacobs R, Ghosh N. Checkpoint inhibitors hodgkin lymphoma and non-hodgkin lymphoma. Curr Hematol Malig Rep. 2018;13:543–54.

pubmed: 30338457 doi: 10.1007/s11899-018-0484-4

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy. Biol Blood Marrow Transpl. 2019;25:2305–21.

doi: 10.1016/j.bbmt.2019.08.015

Tun AM, Ansell SM. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. Cancer Treat Rev. 2020;88:102042.

pubmed: 32521386 doi: 10.1016/j.ctrv.2020.102042

Klyuchnikov E, Bacher U, Kroll T, Shea TC, Lazarus HM, Bredeson C, et al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Bone Marrow Transplant. 2014;49:1–7.

pubmed: 23708703 doi: 10.1038/bmt.2013.72

Richard-Carpentier G, DiNardo CD. Single-agent and combination biologics in acute myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2019;1:548–56.

doi: 10.1182/hematology.2019000059

Choi JH, Bogenberger JM, Tibes R. Targeting apoptosis in acute myeloid leukemia: current status and future directions of BCL-2 inhibition with venetoclax and beyond. Target Oncol. 2020;15:147–62.

pubmed: 32319019 doi: 10.1007/s11523-020-00711-3

Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014;28:289–92.

pubmed: 23760400 doi: 10.1038/leu.2013.176

Percival ME, Tao L, Medeiros BC, Clarke CA. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: a SEER database analysis. Cancer. 2015;121:2004–12.

pubmed: 25739348 doi: 10.1002/cncr.29319

Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Onco Targets Ther. 2016;9:4937–57.

pubmed: 27570458 pmcid: 4986686 doi: 10.2147/OTT.S102504

Chen AT, Prchal JT. JAK2 kinase inhibitors and myeloproliferative disorders. Curr Opin Hematol. 2010;17:110–6.

pubmed: 20087176 doi: 10.1097/MOH.0b013e3283366b91

Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol. 2016;91:50–58.

pubmed: 26492355 doi: 10.1002/ajh.24221

Balassa K, Griffiths A, Winstone D, Li Y, Rocha V, Pawson R. Attrition at the final donor stage among unrelated haematopoietic stem cell donors: the British Bone Marrow Registry experience. Transfus Med. 2019;29:332–7.

pubmed: 31209947 doi: 10.1111/tme.12613

Pidala J, Mupfudze TG, Payton T, Barker J, Perales MA, Shaw BE, et al. Urgent time to allogeneic hematopoietic cell transplantation: a national survey of transplant physicians and unrelated donor search coordinators facilitated by the histocompatibility advisory group to the national marrow donor program. Biol Blood Marrow Transpl. 2019;25:2501–6.

doi: 10.1016/j.bbmt.2019.08.002

Dehn J, Setterholm M, Buck K, Kempenich J, Beduhn B, Gragert L, et al. HapLogic: a predictive human leukocyte antigen-matching algorithm to enhance rapid identification of the optimal unrelated hematopoietic stem cell sources for transplantation. Biol Blood Marrow Transpl. 2016;22:2038–46.

doi: 10.1016/j.bbmt.2016.07.022

Fuchs E, O’Donnell PV, Brunstein CG. Alternative transplant donor sources: is there any consensus? Curr Opin Oncol. 2013;25:173–9.

pubmed: 23385861 doi: 10.1097/CCO.0b013e32835d815f

Kindwall-Keller TL, Ballen KK. Alternative donor graft sources for adults with hematologic malignancies: a donor for all patients in 2017! Oncologist. 2017;22:1125–34.

pubmed: 28546462 pmcid: 5599191 doi: 10.1634/theoncologist.2017-0009

Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transpl. 2018;53:1139–48.

doi: 10.1038/s41409-018-0153-1

D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transpl. 2020;26:e177–e182.

doi: 10.1016/j.bbmt.2020.04.013

Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573–e584.

pubmed: 31477550 doi: 10.1016/S2352-3026(19)30158-9

Ruggeri A, Labopin M, Savani B, Paviglianiti A, Blaise D, Volt F, et al. Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. Bone Marrow Transpl. 2019;54:1987–94.

doi: 10.1038/s41409-019-0582-5

Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:12–24.

doi: 10.1038/s41409-019-0499-z

Tiercy JM. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica. 2016;101:680–7.

pubmed: 27252513 pmcid: 5013969 doi: 10.3324/haematol.2015.141119

Baker M, Wang H, Rowley SD, Cai L, Pecora AL, Skarbnik A, et al. Comparative outcomes after haploidentical or unrelated donor bone marrow or blood stem cell transplantation in adult patients with hematological malignancies. Biol Blood Marrow Transpl. 2016;22:2047–55.

doi: 10.1016/j.bbmt.2016.08.003

Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, Solh M, et al. Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transpl. 2016;22:125–33.

doi: 10.1016/j.bbmt.2015.09.002

Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46.

pubmed: 32375860 pmcid: 7201995 doi: 10.1186/s13045-020-00882-6

Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for hodgkin lymphoma: a registry study of the lymphoma working party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017;35:3425–32.

pubmed: 28846465 doi: 10.1200/JCO.2017.72.6869

Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, et al. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019;3:360–9.

pubmed: 30723110 pmcid: 6373757 doi: 10.1182/bloodadvances.2018027748